Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior

Neuropsychopharmacology

Volumn 40, Issue 3, 2015, Pages 640-649

  Colizzi, Marco ^a,b   Fazio, Leonardo ^a   Ferranti, Laura ^a,c   Porcelli, Annamaria ^a   Masellis, Rita ^a   Marvulli, Daniela ^a   Bonvino, Aurora ^a   Ursini, Gianluca ^a,d   Blasi, Giuseppe ^a   Bertolino, Alessandro ^a,e  

^a UNIVERSITY OF BARI   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PERUGIA   (Italy)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; CANNABIS; MESSENGER RNA; UNCLASSIFIED DRUG; CANNABINOID 1 RECEPTOR; CNR1 PROTEIN, HUMAN;

ABSTINENCE; ADULT; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CANNABIS USE; CONNECTOME; DRINKING BEHAVIOR; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VIVO STUDY; INTELLIGENCE QUOTIENT; MALE; NORMAL HUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; REACTION TIME; TOBACCO DEPENDENCE; TOBACCO USE; VENTROLATERAL PREFRONTAL CORTEX; WORKING MEMORY; CANNABIS SMOKING; DRUG EFFECTS; FUNCTIONAL NEUROIMAGING; GENETIC VARIATION; GENETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; SHORT TERM MEMORY; SINGLE NUCLEOTIDE POLYMORPHISM;

ALCOHOL DRINKING; FEMALE; FUNCTIONAL NEUROIMAGING; GENETIC VARIATION; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA SMOKING; MEMORY, SHORT-TERM; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; TOBACCO USE;

EID: 84922072723     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.213     Document Type: Article

References (51)

1. Barnes JJ, Dean AJ, Nandam LS, O'Connell RG, Bellgrove MA (2011). The molecular genetics of executive function: role of monoamine system genes. Biol Psychiatry 69: 127-143.
2. Beckmann CF, DeLuca M, Devlin JT, Smith SM (2005). Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci 360: 1001-1013.
3. Bell AJ, Sejnowski TJ (1995). An information-maximization approach to blind separation and blind deconvolution. Neural Comput 7: 1129-1159.
4. Bertolino A, Taurisano P, Pisciotta NM, Blasi G, Fazio L, Romano R et al (2010). Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One 5: e9348.
5. Blasi G, De Virgilio C, Papazacharias A, Taurisano P, Gelao B, Fazio L et al (2013a). Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiatry 70: 921-930.
6. Blasi G, Napolitano F, Ursini G, Di Giorgio A, Caforio G, Taurisano P et al (2013b). Association of GSK-3b genetic variation with GSK-3b expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Am J Psychiatry 170: 868-876.
7. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75: 470-478.
8. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002). Dose-related neurocognitive effects of marijuana use. Neurology 59: 1337-1343.
9. Calhoun VD, Adali T, Pearlson GD, Pekar JJ (2001). A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp 14: 140-151.
10. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57: 1117-1127.
11. Chan AW, Pristach EA, Welte JW, Russell M (1993). Use of the TWEAK test in screening for alcoholism/heavy drinking in three populations. Alcohol Clin Exp Res 17: 1188-1192.
12. Chavarr?á-Siles I, Contreras-Rojas J, Hare E, Walss-Bass C, Quezada P, Dassori A et al (2008). Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147: 279-284.
13. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al (2011). Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 478: 519-523.
14. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
15. Dalton VS, Long LE, Weickert CS, Zavitsanou K (2011). Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 36: 1620-1630.
16. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A et al (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72: 811-816.
17. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991). The Fagerström Test fot Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 86: 1119-1127.
18. Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J et al (2008). The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 65: 841-850.
19. Gottesman II, Gould TD (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636-645.
20. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T (2003). Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. Int Neuropsychol Soc 9: 679-689.
21. He H, Sui J, Yu Q, Turner JA, Ho BC, Sponheim SR et al (2012). Altered small-world brain networks in schizophrenia patients during working memory performance. PLoS One 7: e38195.
22. Himberg J, Hyvärinen A, Esposito F (2004). Validating the independent components of neuroimaging time series via clustering and visualization. Neuroimage 22: 1214-1222.
23. Jockers-Scherübl MC, Wolf T, Radzei N, Schlattmann P, Rentzsch J, Gómez-Carrillo de Castro A et al (2007). Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 31: 1054-1063.
24. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA (2004). Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl) 176: 239-247.
25. Kim DI, Manoach DS, Mathalon DH, Turner JA, Mannell M, Brown GG et al (2009). Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum Brain Mapp 30: 3795-3811.
26. Lane SD, Cherek DR, Lieving LM, Tcheremissine OV (2005). Marijuana effects on human forgetting functions. J Exp Anal Behav 83: 67-83.
27. Li YO, Adali T, Calhoun VD (2007). Estimating the number of independent components for functional magnetic resonance imaging data. Hum Brain Mapp 28: 1251-1266.
28. Mata I, Rodrguez-Sánchez JM, Pelayo-Terán JM, Pérez-Iglesias R, González-Blanch C, Ramrez-Bonilla M et al (2008). Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol Med 38: 1257-1266.
29. Matsuda LA (1997). Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 11: 143-166.
30. Mouslech Z, Valla V (2009). Endocannabinoid system: An overview of its potential in current medical practice. Neuro Endocrinol Lett 30: 153-179.
31. Pazos MR, Núñez E, Benito C, Tolón RM, Romero J (2005). Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 81: 239-247.
32. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
33. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001). Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58: 909-915.
34. Ruiz-Contreras AE, Carrillo-Sánchez K, Gómez-López N, Vadillo-Ortega F, Hernández-Morales S, Carnevale-Cantoni A et al (2013). Working memory performance in young adults is associated to the AATn polymorphism of the CNR1 gene. Behav Brain Res 236: 62-66.
35. Ruiz-Contreras AE, Carrillo-Sánchez K, Ortega-Mora I, Barrera-Tlapa MA, Romań-López TV, Rosas-Escobar CV et al (2014). Performance in working memory and attentional control is associated with the rs2180619 SNP in the CNR1 gene. Genes Brain Behav 13: 173-178.
36. Sambataro F, Blasi G, Fazio L, Caforio G, Taurisano P, Romano R et al (2010). Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia. Neuropsychopharmacology 35: 904-912.
37. Schacht JP, Hutchison KE, Filbey FM (2012). Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology 37: 2368-2376.
38. Schmithorst VJ, Holland SK, Plante E (2006). Cognitive modules utilized for narrative comprehension in children: a functional magnetic resonance imaging study. Neuroimage 29: 254-266.
39. Schmithorst VJ, Holland SK, Plante E (2007). Object identification and lexical/semantic access in children: a functional magnetic resonance imaging study of word-picture matching. Hum Brain Mapp 28: 1060-1074.
40. Schnell T, Koethe D, Daumann J, Gouzoulis-Mayfrank E (2009). The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl) 205: 45-52.
41. Seifert J, Ossege S, Emrich HM, Schneider U, Stuhrmann M (2007). No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett 426: 29-33.
42. Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E et al (2007). Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res 92: 74-84.
43. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M et al (2002). Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287: 1123-1131.
44. Solowij N, Michie PT (2007). Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32: 30-52.
45. Thompson-Schill SL, D'Esposito M, Aguirre GK, Farah MJ (1997). Role of left inferior prefrontal cortex in retrieval of semantic knowledge: a reevaluation. Proc Natl Acad Sci USA 94: 14792-14797.
46. van Winkel R, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011b). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 68: 148-157.
47. van Winkel R, van Beveren NJ, Simons C, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011a). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 36: 2529-2537.
48. Verdejo-Garc?á A, Beatriz Fagundo A, Cuenca A, Rodriguez J, Cuyás E, Langohr K et al (2013). COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology 38 1598-1606.
49. Wagner AD, Maril A, Bjork RA, Schacter DL (2001). Prefrontal contributions to executive control: fMRI evidence for functional distinctions within lateral Prefrontal cortex. Neuroimage 14: 1337-1347.
50. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al (2001). Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50: 825-844.
51. Xu J, Zhang S, Calhoun VD, Monterosso J, Li CS, Worhunsky PD et al (2013). Task-related concurrent but opposite modulations of overlapping functional networks as revealed by spatial ICA. Neuroimage 79: 62-71.